Fractyl Health Seeks Shareholder Nod for $23M Warrant Exercise

TL;DR

**GUTS needs this warrant approval to keep the lights on and trials running; vote FOR or watch your investment dilute anyway as they scramble for cash.**

AI Summary

Fractyl Health, Inc. (GUTS) is seeking stockholder approval for the issuance of up to 21,904,761 shares of common stock upon the exercise of Tranche B Warrants, which were part of a financing transaction that closed on August 7, 2025. This offering generated approximately $20.7 million in net proceeds for the company. The funds are intended to support the Revita and Rejuva pipeline programs, extend the cash runway through key 3- and 6-month REMAIN-1 Midpoint Cohort randomized data readouts, and for general corporate purposes. The Tranche B Warrants have an initial exercise price of $1.05 per share and are not exercisable until stockholder approval is obtained, as required by Nasdaq Listing Rule 5635(d). If approved, the full exercise of these warrants could bring an additional $23.0 million in gross proceeds but would dilute existing stockholders by 21,904,761 shares. The Board of Directors, officers, and Mithril LP, collectively holding approximately 21% of voting power, have agreed to vote in favor of this proposal.

Why It Matters

This vote is critical for Fractyl Health's financial stability and its ability to fund crucial clinical trials for its Revita and Rejuva pipeline programs, directly impacting its competitive position in the metabolic disease space. Failure to approve the warrant exercise could starve the company of an additional $23.0 million in capital, potentially delaying or halting product development and making future financing difficult. For investors, this represents a trade-off between immediate capital infusion and potential dilution, while employees and customers are directly affected by the company's ability to advance its therapeutic candidates. The broader market will watch to see if GUTS can successfully navigate this financing structure and continue its development efforts against larger pharmaceutical competitors.

Risk Assessment

Risk Level: medium — The company explicitly states that failure to obtain stockholder approval for the Tranche B Warrants could result in not receiving approximately $23.0 million in gross proceeds, adversely impacting its business and financial condition, including funding operations and advancing clinical trials. Furthermore, the company has agreed to seek approval every 30 days, incurring substantial costs and management distraction, which presents an ongoing operational risk.

Analyst Insight

Investors should vote 'FOR' Proposal No. 1 to ensure Fractyl Health receives the crucial $23.0 million in additional funding from the Tranche B Warrants, which is vital for advancing its pipeline programs and extending its cash runway. While dilution is a concern, the alternative of not securing this capital poses a greater risk to the company's operational viability and future financing prospects.

Key Numbers

• $20.7M — Net proceeds from the Offering (Received by Fractyl Health from the financing transaction closed on August 7, 2025)
• 21,904,761 — Shares of common stock underlying Tranche B Warrants (Potential shares to be issued upon exercise, subject to stockholder approval)
• $1.05 — Initial exercise price per share for Tranche B Warrants (The price at which Tranche B Warrants can be exercised)
• $23.0M — Additional gross proceeds if all Tranche B Warrants are cash exercised (Crucial funding for operations and clinical trials if Proposal No. 1 is approved)
• 50,289,014 — Shares of common stock outstanding (As of the Record Date, August 6, 2025)
• 21% — Voting power held by directors, officers, and Mithril (These parties have agreed to vote in favor of Proposal No. 1)
• October 3, 2025 — Date of Special Meeting of Stockholders (When stockholders will vote on the proposals)
• August 6, 2025 — Record Date for Special Meeting (Determines which stockholders are entitled to vote)
• 12.8% — Beneficial ownership by entities affiliated with Mithril (Largest beneficial owner as of August 6, 2025)
• 5.5% — Beneficial ownership by Harith Rajagopalan, M.D., Ph.D. (CEO's beneficial ownership as of August 6, 2025)

Key Players & Entities

• FRACTYL HEALTH, INC. (company) — Registrant seeking stockholder approval
• Nasdaq (regulator) — Stock exchange requiring stockholder approval under Listing Rule 5635(d)
• Ladenburg Thalmann & Co., Inc. (company) — Underwriter for the financing transaction
• Harith Rajagopalan, M.D., Ph.D. (person) — Co-Founder, Chief Executive Officer and Director of Fractyl Health, Inc.
• Mithril LP (company) — Beneficial owner and party to the Voting Agreement
• Mithril II LP (company) — Beneficial owner and party to the Voting Agreement
• Sarah Toomey (person) — General Counsel and Corporate Secretary of Fractyl Health, Inc.
• CVF, LLC (company) — 5% or greater stockholder
• Maverick Capital (company) — 5% or greater stockholder
• General Catalyst (company) — 5% or greater stockholder

FAQ

Risk Factors

• Dilution from Warrant Exercise [medium — financial]: The company is seeking stockholder approval to issue up to 21,904,761 shares of common stock upon the exercise of Tranche B Warrants. If fully exercised, this would result in significant dilution to existing stockholders, as these shares represent a substantial portion of the currently outstanding shares.
• Reliance on Future Financing [high — financial]: The company's ability to fund its Revita and Rejuva pipeline programs and extend its cash runway relies on the exercise of Tranche B Warrants and potentially future financing. The $20.7 million in net proceeds from the August 7, 2025 transaction may not be sufficient for long-term operations.
• Nasdaq Listing Rule Compliance [medium — regulatory]: The issuance of shares upon exercise of the Tranche B Warrants requires stockholder approval due to Nasdaq Listing Rule 5635(d). Failure to obtain this approval would prevent the exercise of these warrants, impacting the company's ability to raise additional capital.

Industry Context

Fractyl Health operates in the biotechnology sector, focusing on developing therapies for metabolic and inflammatory diseases. This sector is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Success often depends on clinical trial outcomes and the ability to secure substantial funding for pipeline advancement.

Regulatory Implications

The company must comply with Nasdaq Listing Rules, specifically Rule 5635(d), which requires shareholder approval for issuances of securities that could result in a 20% or greater change in outstanding common stock or voting power. Obtaining this approval is critical for the exercise of the Tranche B Warrants.

What Investors Should Do

1. Review the details of Proposal No. 1 regarding the issuance of shares upon exercise of Tranche B Warrants.
2. Assess the company's cash runway and funding needs.
3. Consider the voting intentions of major shareholders and management.

Key Dates

• 2025-08-07: Financing transaction closed — Generated approximately $20.7 million in net proceeds for the company.
• 2025-08-06: Record Date for Special Meeting — Determined the stockholders entitled to vote at the special meeting.
• 2025-10-03: Special Meeting of Stockholders — Stockholders will vote on proposals, including the issuance of shares related to Tranche B Warrants.

Glossary

DEF 14A

A proxy statement filed with the SEC by publicly traded companies to solicit shareholder votes for an upcoming meeting. (This document contains the information about the proposed warrant exercise and other corporate actions requiring shareholder approval.)

Tranche B Warrants

Specific warrants issued as part of a financing transaction that are subject to stockholder approval for exercise. (The exercise of these warrants is the primary subject of the special meeting and could result in significant share issuance and capital infusion.)

Net Proceeds

The amount of money a company receives from a transaction after deducting any fees or expenses. (Indicates the actual cash raised by the company from the August 7, 2025 financing, which was $20.7 million.)

Dilution

The reduction in the ownership percentage of existing shareholders when new shares are issued. (The exercise of Tranche B Warrants will dilute existing shareholders' ownership stakes.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends, vote on corporate matters, or participate in other shareholder rights. (August 6, 2025, was the record date to determine who could vote at the special meeting.)

Beneficial Ownership

The ultimate ownership of an asset, such as stock, even if the legal title is held by someone else. It includes the power to vote or direct the voting of the shares, or to dispose of or direct the disposition of the shares. (Used to identify major shareholders and management's holdings, as detailed in the 'Security Ownership' section.)

Year-Over-Year Comparison

This filing is a DEF 14A, a proxy statement for a special meeting, and does not directly compare financial metrics to a prior period's annual report. However, it highlights a recent financing transaction on August 7, 2025, which generated $20.7 million in net proceeds. The primary focus is on seeking shareholder approval for warrant exercises, which will impact future share counts and capital structure, rather than reporting historical financial performance changes.

Key Financial Figures

• $0.00001 — g shares of our common stock, par value $0.00001 per share, at the close of business on
• $1.05 — 201d;), at a combined offering price of $1.05 for each share of common stock, accompa
• $20.7 m — us from the Offering were approximately $20.7 million, and the Offering closed on Augus
• $1 — cise price per share of common stock of $1.05, subject to certain adjustments. Th
• $0.125 — Nasdaq generally attributes a value of $0.125 for each warrant offered with a share o
• $23.0 — itional gross proceeds of approximately $23.0 million. If the Tranche B Warrants
• $12.00 — arrants at an assumed exercise price of $12.00. HCC Manager LLC, manager of CVF, LLC,

Filing Documents

• ny20053353x2_def14a.htm (DEF 14A) — 204KB
• logo_fractyl.jpg (GRAPHIC) — 64KB
• ny20053353x1_pc01.jpg (GRAPHIC) — 571KB
• ny20053353x1_pc02.jpg (GRAPHIC) — 583KB
• sig_hrajagopalan.jpg (GRAPHIC) — 23KB
• sig_stoomey.jpg (GRAPHIC) — 19KB
• sig_stoomeyx1.jpg (GRAPHIC) — 17KB
• 0001140361-25-032517.txt ( ) — 1963KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT     6 QUESTIONS AND ANSWERS ABOUT THE SPECIAL MEETING OF STOCKHOLDERS     9 ADDITIONAL INFORMATION     13

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS     15         For a disclaimer regarding forward-looking statements in this proxy statement, please refer to - Forward-Looking Statements . i TABLE OF CONTENTS   Fractyl Health, Inc. 3 Van de Graaff Drive, Suite 200 Burlington, Massachusetts 01803   EXECUTIVE SUMMARY Special Meeting Information Date and Time: Friday, October 3, 2025, 10:00 a.m. Eastern Time Location: www.virtualshareholdermeeting.com/GUTS2025SM Record Date: August 6, 2025 Proxy Mail Date: On or about August 27, 2025 How to Vote Before the Special Meeting: • By Internet: Visit the website listed on your proxy card • By Phone: Call the telephone number on your proxy card • By Mail: If you received paper copies, sign, date and return your proxy card in the provided envelope During the Special Meeting: • Participate in the Special Meeting webcast using your 16-digit control number This proxy statement is furnished in connection with the solicitation by the Board of Directors (the “Board”) of Fractyl Health, Inc. (the “Company,” “Fractyl Health,” “we” or “us”) of proxies to be voted at our Special Meeting of Stockholders to be held on Friday, October 3, 2025 (the “Special Meeting”), at 10:00 a.m. Eastern Time, and at any continuation, postponement or adjournment of the Special Meeting. The Special Meeting will be a completely virtual meeting, which will be conducted via live webcast. You will be able to attend the Special Meeting online by visiting www.virtualshareholdermeeting.com/GUTS2025SM and entering your 16-digit control number included on your proxy card. Only holders of record of outstanding shares of our common stock, par value $0.00001 per share, at the close of business on August 6, 2025 (the “Record Date”), will be entitled

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth information as of August 6, 2025 with respect to the beneficial ownership of our common stock by: • each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of common stock; • each of our named executive officers; • each of our directors; and • all of our executive officers and directors as a group. The number of shares beneficially owned by each stockholder is determined in accordance with the rules issued by the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power, which includes the power to dispose of or to direct the disposition of such security. Except as indicated in the footnotes below, we believe, based on the information furnished to us, that the individuals and entities named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned by them, subject to any community property laws. Percentage ownership of our common stock is based on 50,289,014 shares of our common stock outstanding as of August 6, 2025. In computing the number of shares beneficially owned by an individual or entity and the percentage ownership of that person, shares of common stock subject to options, RSUs, warrants or other rights held by such person that are currently exercisable or vested, or will become exercisable or vest within 60 days of August 6, 2025 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. Unless noted otherwise, the address of all listed stockholders is c/o Fractyl Health, Inc., 3 Van de Graaff Drive, Suite 20

View Full Filing

View this DEF 14A filing on SEC EDGAR